» Articles » PMID: 15860571

A Farnesoid X Receptor-small Heterodimer Partner Regulatory Cascade Modulates Tissue Metalloproteinase Inhibitor-1 and Matrix Metalloprotease Expression in Hepatic Stellate Cells and Promotes Resolution of Liver Fibrosis

Overview
Specialty Pharmacology
Date 2005 Apr 30
PMID 15860571
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

The farnesoid X receptor (FXR) is expressed by and regulates hepatic stellate cells (HSCs). In the present study, we investigated whether 6-ethyl chenodeoxycholic acid (6-ECDCA or INT-747), a semisynthetic derivative of chenodeoxycholic acid (CDCA), modulates tissue metalloproteinase inhibitor (TIMP)-1 and matrix metalloprotease (MMP)-2 expression/activity in HSCs and in the liver of rats rendered cirrhotic by 4-week administration of CCl(4). Exposure of HSCs to FXR ligands increases small heterodimer partner (SHP) mRNA by 3-fold and reduces basal and thrombin-stimulated expression of alpha1(I)collagen, alpha-smooth muscle actin (alpha-SMA), TIMP-1, and TIMP-2 by approximately 60 to 70%, whereas it increased matrix metalloprotease (MMP)-2 activity by 2-fold. In coimmunoprecipitation, electromobility shift, and transactivation experiments, FXR activation/overexpression caused a SHP-dependent inhibition of JunD binding to its consensus element in the TIMP-1 promoter. Inhibition of TIMP-1 expression by SHP overexpression enhanced the sensitivity of HSCs to proapoptogenic stimuli. Administration of 3 mg/kg 6-ECDCA, but not 15 mg/kg ursodeoxycholic acid, resulted in early (3-5-day) induction of SHP and prevention of early up-regulation of TIMP-1 mRNA induced by CCl(4). In the prevention protocol, 4-week administration of 6-ECDCA reduced alpha1(I)collagen, alpha-SMA, and TIMP-1 mRNA by 60 to 80%, whereas it increased MMP-2 activity by 5-fold. In the resolution protocol, administration of 3 mg/kg 6-ECDCA promoted liver fibrosis resolution and increased the apoptosis of nonparenchyma liver cells. By demonstrating that a FXR-SHP regulatory cascade promotes the development of a quiescent phenotype and increases apoptosis of HSCs, this study establishes that FXR ligands may be beneficial in treatment of liver fibrosis.

Citing Articles

Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments.

Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E Cells. 2024; 13(19.

PMID: 39404413 PMC: 11475195. DOI: 10.3390/cells13191650.


Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches.

Mohammed O, Attia H, Mohamed B, Elbaset M, Fayed H J Pharm Pharm Sci. 2023; 26:11808.

PMID: 38022905 PMC: 10662312. DOI: 10.3389/jpps.2023.11808.


High-cholesterol diet in combination with hydroxypropyl-beta-cyclodextrin induces NASH-like disorders in the liver of rats.

Saigo Y, Sasase T, Tohma M, Uno K, Shinozaki Y, Maekawa T Physiol Res. 2023; 72(3):371-382.

PMID: 37449749 PMC: 10668992. DOI: 10.33549/physiolres.934981.


Bile acid-mediated signaling in cholestatic liver diseases.

Zeng J, Fan J, Zhou H Cell Biosci. 2023; 13(1):77.

PMID: 37120573 PMC: 10149012. DOI: 10.1186/s13578-023-01035-1.


Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions.

Yang J, Tang X, Liang Z, Chen M, Sun L Clin Mol Hepatol. 2023; 29(2):465-481.

PMID: 36800698 PMC: 10121313. DOI: 10.3350/cmh.2022.0327.